Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risperidone

This publication has 9 references indexed in Scilit:

• In vivo properties of SB 200646A, a 5‐HT_2C/2B receptor antagonist
  British Journal of Pharmacology, 1994
• Survey on the pharmacodynamics of the new antipsychotic risperidone
  Psychopharmacology, 1994
• Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist
  Journal of Medicinal Chemistry, 1993
• A proposed new nomenclature for 5-HT receptors
  Trends in Pharmacological Sciences, 1993
• 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine
  European Journal of Pharmacology, 1992
• Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors
  Neuroscience & Biobehavioral Reviews, 1992
• Neurochemical and in vivo pharmacological profile of sertindole, a limbic‐selective neuroleptic compound
  Drug Development Research, 1991
• Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites
  European Journal of Pharmacology, 1990
• Discriminative stimulus properties of the serotonergic agent 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)
  Life Sciences, 1986